Cargando…

Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease

The discouraging results with therapies for Alzheimer’s disease (AD) in clinical trials, highlights the urgent need to adopt new approaches. Like other complex diseases, it is becoming clear that AD therapies should focus on the simultaneous modulation of several targets implicated in the disease. R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuadrado-Tejedor, Mar, Pérez-González, Marta, García-Muñoz, Cristina, Muruzabal, Damián, García-Barroso, Carolina, Rabal, Obdulia, Segura, Víctor, Sánchez-Arias, Juan A., Oyarzabal, Julen, Garcia-Osta, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597953/ https://www.ncbi.nlm.nih.gov/pubmed/31281249 http://dx.doi.org/10.3389/fnagi.2019.00149

Ejemplares similares

Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease
por: Cuadrado-Tejedor, M., et al.
Publicado: (2015)

Novel pharmacological maps of protein lysine methyltransferases: key for target deorphanization
por: Rabal, Obdulia, et al.
Publicado: (2018)

CHEMDNER: The drugs and chemical names extraction challenge
por: Krallinger, Martin, et al.
Publicado: (2015)

LimTox: a web tool for applied text mining of adverse event and toxicity associations of compounds, drugs and genes
por: Cañada, Andres, et al.
Publicado: (2017)

Current Animal Models of Alzheimer’s Disease: Challenges in Translational Research
por: Cuadrado-Tejedor, Mar, et al.
Publicado: (2014)

Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice
por: Lasarte-Cia, Aritz, et al.
Publicado: (2018)

The Markyt visualisation, prediction and benchmark platform for chemical and gene entity recognition at BioCreative/CHEMDNER challenge
por: Pérez-Pérez, Martin, et al.
Publicado: (2016)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor
por: Lozano, Teresa, et al.
Publicado: (2017)

Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)
por: Soldevilla, Mario Martínez, et al.
Publicado: (2017)

Histone Deacetylases: Transcriptional Regulation and other Cellular Functions
por: Garcia-Manero, G
Publicado: (2007)

Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome
por: Rodriguez-Madoz, Juan Roberto, et al.
Publicado: (2017)

Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase Inhibitors
por: Saluste, Gustavo, et al.
Publicado: (2012)

Docosahexaenoic Acid Ameliorates Contextual Fear Memory Deficits in the Tg2576 Alzheimer’s Disease Mouse Model: Cellular and Molecular Correlates
por: Badesso, Sara, et al.
Publicado: (2022)

Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition
por: Peixoto, Christina Alves, et al.
Publicado: (2015)

Histone deacetylases modulate resistance to the therapy in lung cancer
por: Contreras-Sanzón, Estefanía, et al.
Publicado: (2022)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice
por: Pascual-Lucas, Maria, et al.
Publicado: (2014)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms
por: Celay, Jon, et al.
Publicado: (2018)

Identifying the Main Functional Pathways Associated with Cognitive Resilience to Alzheimer’s Disease
por: Pérez-González, Marta, et al.
Publicado: (2021)

Taking advantage of saliva
por: Van Epps, Heather L.
Publicado: (2006)

Hypothalamic leptin action is mediated by histone deacetylase 5
por: Kabra, Dhiraj G., et al.
Publicado: (2016)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

How to Take Advantage of Mentorship
por: Singla, Manish B.
Publicado: (2015)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

SIRT6 histone deacetylase functions as a potential oncogene in human melanoma
por: Garcia-Peterson, Liz Mariely, et al.
Publicado: (2017)

Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
por: Hai, Yang, et al.
Publicado: (2017)

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
por: Chavez-Blanco, Alma, et al.
Publicado: (2005)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylases in RA: epigenetics and epiphenomena
por: Grabiec, Aleksander M, et al.
Publicado: (2010)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_r41r6etqj8vh8ttc531i9j8tkv